Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
Merck
Express Scripts
Cipla
Daiichi Sankyo
Fuji
Chinese Patent Office
Moodys
Federal Trade Commission

Generated: October 23, 2017

DrugPatentWatch Database Preview

Bazedoxifene acetate; estrogens, conjugated - Generic Drug Details

« Back to Dashboard

What are the generic sources for bazedoxifene acetate; estrogens, conjugated and what is the scope of bazedoxifene acetate; estrogens, conjugated patent protection?

Bazedoxifene acetate; estrogens, conjugated
is the generic ingredient in one branded drug marketed by Wyeth Pharms Pfizer and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bazedoxifene acetate; estrogens, conjugated has sixty-four patent family members in forty countries and ten supplementary protection certificates in nine countries.

There are three drug master file entries for bazedoxifene acetate; estrogens, conjugated. Two suppliers are listed for this compound.

Summary for Generic Name: bazedoxifene acetate; estrogens, conjugated

US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: see list3
Suppliers / Packagers: see list2
Clinical Trials: see list1,217
Drug Prices:see low prices
DailyMed Link:bazedoxifene acetate; estrogens, conjugated at DailyMed

Pharmacology for Ingredient: bazedoxifene acetate; estrogens, conjugated

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: bazedoxifene acetate; estrogens, conjugated

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: bazedoxifene acetate; estrogens, conjugated

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,127,404 Tissue selective compounds in the treatment of endometrial proliferation► Subscribe
7,041,6632-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,449,4552-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,835,729 2-phenyl-1-[4(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,247,6242-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,326,367 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,132,4172-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,232,307 Tissue selective compounds in the treatment of ovarian cancer► Subscribe
6,787,538 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,924,281 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: bazedoxifene acetate; estrogens, conjugated

Country Document Number Estimated Expiration
JapanH1036346► Subscribe
Denmark0802183► Subscribe
Brazil9715334► Subscribe
South Korea20060135866► Subscribe
Australia1892097► Subscribe
Panama8629101► Subscribe
Luxembourg91608► Subscribe
Israel120701► Subscribe
Norway2009025► Subscribe
New Zealand314601► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB09/045United Kingdom► SubscribePRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/09/511/001 20090417; UK EU/1/09/511/002 20090417; UK EU/1/09/511/003 20090417; UK EU/1/09/511/004 20090417
608Luxembourg► Subscribe91608, EXPIRES: 20220415
0802183/01Switzerland► SubscribePRODUCT NAME: BAZEDOXIFEN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58732 12.01.2010
2009007,C0802183Lithuania► SubscribePRODUCT NAME: BAZEDOXIFENUM; REGISTRATION NO/DATE: EU/1/09/511/001 - EU/1/09/511/004 20090417
0416Netherlands► Subscribe300416, 20170415, EXPIRES: 20220414
2009 00035Denmark► Subscribe
C0048France► SubscribePRODUCT NAME: BAZEDOXIFENE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/09/511/001 DU 20090417; REGISTRATION NO/DATE AT EEC: EU/1/09/511/001-004 DU 20090417
09/028Ireland► SubscribePRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/09/511/001-004 20090417
4Finland► Subscribe
2009007Lithuania► SubscribePRODUCT NAME: BAZEDOXIFENUM; REGISTRATION NO/DATE: EU/1/09/511/001 - EU/1/09/511/004 20090417
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Cantor Fitzgerald
US Department of Justice
Fuji
Novartis
AstraZeneca
Accenture
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot